ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1201

Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?

Claire Barber1, Natalie Shiff 2, Cheryl Barnabe 3, Susanne Benseler 3, Ricky Chin 3, Nicole Johnson 3, Nadia Luca 3, Paivi Miettunen 4, Marinka Twilt 3, Dwaraka Veeramreddy 3 and Heinrike Schmeling 5, 1University of Calgary, Calgary, Canada, 2University of Florida, Gainesville, FL, 3University of Calgary, Calgary, AB, Canada, 4Alberta Children's Hospital, Calgary, ON, Canada, 5Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: juvenile idiopathic arthritis (JIA), Quality Indicators and benchmarking tools, quality of care, wait times

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Measures Of Healthcare Quality Poster II: Improving Care

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Wait time to pediatric rheumatology care for patients with Juvenile Idiopathic Arthritis (JIA) is a nationally endorsed quality measure in Canada. Target wait times for systemic JIA are 7 days from referral to pediatric rheumatology care, and 4 weeks for other JIA categories. The purpose of this study was to measure this quality indicator and evaluate factors associated with JIA wait times at a single academic pediatric rheumatology center.

Methods: This was a retrospective cohort study of patients with a diagnosis of JIA participating in a pharmacogenetics study who had demographic and disease-related data collected prospectively between 2002-2018. The time between referral date and first pediatric rheumatology visit was extracted from clinic charts and clinical variables from a pharmacogenetics study database. Factors evaluated included JIA category, age, sex, distance from the clinic, baseline number of active joints, pain and C-reactive protein (CRP) at the first clinic visit. Distance from clinic was calculated by geocoding the latitude and longitude of the patient’s postal code using the Postal Code Conversion File, with distance calculations made using ArcGIS by calculating the shortest distance to the clinic using roadways. Urban versus rural classification of patient residence was according to Statistics Canada definitions. Descriptive characteristics and wait time measures are reported using medians (interquartile range, IQR) given the non-normal distributions. Non-parametric Kruskal-Wallis rank test was used to examine whether there was any difference in wait times among patients with different categories of JIA. Cox proportional hazard modelling was used to evaluate potential factors associated with wait time.

Results: 164 patients with JIA were eligible for inclusion, of which 116 were female (71%). The median age at diagnosis was 8.0 (IQR 3.5, 12.0) years. The majority of patients had oligoarticular JIA (n=75, 46%) or rheumatoid factor-negative polyarticular JIA (n=48, 29%) and 6 patients had systemic JIA (4%). The majority of patients (n=102, 62%) were from Calgary. The median network distance for patients between their residence and the clinic was 22.8 kilometers (IQR 13.5, 127.8). There was a median of 22 days between referral and pediatric rheumatologist visit (IQR 9, 45), and there was no significant difference between the wait times among JIA categories (p=0.055). Overall, 62% of JIA cases met the established wait time benchmarks. Using Cox-proportional hazard modeling, higher age was associated with longer wait times (HR 0.94, 95% CI 0.89, 0.98, p=0.005).

Conclusion: The median wait time from referral to pediatric rheumatologist visit for patients with JIA in this study met the national benchmark, although some patients experienced long wait times for appointments. Wait times did not significantly differ by JIA category but older patients waited longer. This work highlights the importance of monitoring of wait times as a quality indicator.


Disclosure: C. Barber, None; N. Shiff, CARRA, 9; C. Barnabe, None; S. Benseler, None; R. Chin, None; N. Johnson, None; N. Luca, None; P. Miettunen, None; M. Twilt, None; D. Veeramreddy, None; H. Schmeling, F. Hoffmann-La Roche Ltd, 2, Janssen, 2, Pfizer, 2, UCB Biosciences GmbH, 2.

To cite this abstract in AMA style:

Barber C, Shiff N, Barnabe C, Benseler S, Chin R, Johnson N, Luca N, Miettunen P, Twilt M, Veeramreddy D, Schmeling H. Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-we-meeting-benchmarks-for-wait-times-to-pediatric-rheumatology-care-for-juvenile-idiopathic-arthritis-jia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-we-meeting-benchmarks-for-wait-times-to-pediatric-rheumatology-care-for-juvenile-idiopathic-arthritis-jia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology